



Yondelis[®] receives the marketing authorization for the treatment of ovarian cancer in Brazil and India

- ***Besides the marketing authorization in Brazil, Yondelis[®] has been approved also for platinum-sensitive recurrent ovarian cancer (ROC) in India and Argentina and the authorities in Lebanon and Costa Rica have approved also the drug for Soft Tissue Sarcoma (STS).***
- ***Yondelis[®] is currently approved in 63 countries.***

Madrid, October 1st 2010: Centocor Ortho Biotech Products, L. P., has informed PharmaMar SA (Grupo Zeltia, ZEL.MC) that the regulatory authorities in Brazil, India and Argentina have issued a marketing authorization of Yondelis[®] in combination with CAELYX[®] (pegylated liposomal doxorubicin hydrochloride) for the treatment of patients with platinum-sensitive ovarian cancer.

In view of the new marketing authorization, Yondelis[®] now has authorization in 63 countries for some indication, 30 of them outside the European Economic Area (EEA). The European Commission (EC) approved Yondelis[®] for platinum-sensitive ovarian cancer in September 2009. Since then, the commercialization has started progressively in Europe and other territories where Yondelis[®] has been approved. In 2007 the EC approved Yondelis[®] for soft tissue sarcoma.

Clinical trials being conducted by PharmaMar are under way to expand the use of Yondelis[®] in sarcoma, including a trial as first-line treatment in patients with translocation-associated tumours and in Ewing's sarcoma, rhabdomyosarcoma and other forms of STS. Yondelis[®] is also undergoing trials in solid tumours, such as breast cancer.



Yondelis® has orphan drug status for soft tissue sarcoma and ovarian cancer in the European Union, the United States, and Switzerland, and for soft tissue sarcoma in South Korea.

According to the licensing agreement between PharmaMar (Zeltia, S.A. subsidiary) and Centocor Ortho Biotech Products, L.P., PharmaMar has the marketing rights to Yondelis® in Europe, while Centocor Ortho Biotech Products, L.P. has the marketing rights to the drug everywhere else, except in Japan, where Taiho Pharmaceutical Co., Ltd. has a licensing agreement for the development and sale of Yondelis®.

About ovarian cancer

In the West, epithelial ovarian cancer represents 4% of all cancers among women and ranks fifth as a cause of female deaths from cancer (American Cancer Society [ACS], Cancer Reference Information, 2005). According to 2009 clinical data from the European Society for Medical Oncology (ESMO), 18 new cases of ovarian cancer are detected each year in the European Union per 100,000 women, and the mortality rate is 12 per 100,000 women per year. The average age of diagnosis is 63, and the incidence increases with age, particularly above the age of 70; however, it may also occur in younger women, especially in those with a family history of the disease. 70% of women with ovarian cancer are diagnosed late, when the disease is already advanced (Stages III and IV). The 5-year survival rate for these women is only 15%-20%, compared with nearly 90% for patients in Stage I of the disease (i.e. the earliest stage) and 70% for Stage II (intermediate).

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first anti-cancer drug. It is currently approved for STS in 31 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC besides Brazil and Canada. Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis® are also under way on prostate, breast, lung and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis® and PM01183. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's



Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information (Tel. +34 91 444 4500)

This note is also available at PharmaMar and Zeltia website: www.pharmamar.com; www.zeltia.com